Image

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market - Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Upcoming Report
  • Nov 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Nov 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market, By Drugs Type (Talazoparib, Veliparib, Olaparib, Others), Indication Type (Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Market Analysis and Insights : Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market

Poly (ADP-Ribose) polymerase (PARP) inhibitors market is expected to gain market growth in the forecast period of 2021-2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 24.7% in the above mentioned forecast period.

Poly (ADP-Ribose) polymerase (PARP) are targeted therapy medicine used for the treatment of cancer. PARP is a macromolecule that helps in repair of cancer cells and facilitates its growth. PARP inhibitors stop the operate of PARP and inhibit the repair pathways of cancer cells. PARP inhibitors are typically used for the treatment of female internal reproductive organ cancer, fallopian tube cancer, carcinoma among others

Rising incidence rate of cancer exacting novel therapies will increase the anticipation of PARP inhibitors driving the market growth. Rising awareness regarding PARP inhibitors for treatment of cancer can also expand the market size. Increasing geriatric population and prevailing cancer will boost the expansion of the market Governmental investment in improvement of health expenditure is another issue provision this market growth.

Side effects of PARP inhibitors hampers the market growth Resistance of PARP inhibitors is another issue restraining the expansion of the market tight regulative policies will prohibit the market growth.

Increasing population and rising awareness about cancer treatment are going to present many opportunities in future for poly (ADP-Ribose) polymerase (PARP) inhibitors market.

This poly (ADP-Ribose) polymerase (PARP) inhibitors market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographical expansions, technological innovations in the market. To gain more info on poly (ADP-Ribose) polymerase (PARP) inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Poly (ADP-Ribose) polymerase (PARP) inhibitors market Scope and Market Size

The poly (ADP-Ribose) polymerase (PARP) inhibitors market is segmented on the basis of drugs type, indication type, end users, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • On the basis of drug type, the poly (ADP-Ribose) polymerase (PARP) inhibitors market is segmented into talazoparib, veliparib, olaparib, and others
  • On the basis of indication type, the poly (ADP-Ribose) polymerase (PARP) inhibitors market is segmented into ovarian cancer, fallopian tube cancer, breast cancer, and others
  • On the basis of end-users, the poly (ADP-Ribose) polymerase (PARP) inhibitors market is segmented into hospitals, homecare, specialty clinics, others
  • The poly (ADP-Ribose) polymerase (PARP) inhibitors market is also segmented on the basis of distribution channel into hospital pharmacy, online pharmacy, retail pharmacy, others

Poly (ADP-Ribose) polymerase (PARP) inhibitors market Country Level Analysis

Poly (ADP-Ribose) polymerase (PARP) inhibitors market is analyzed and market size information is provided by the country, drugs type, indication type, end users, and distribution channel as referenced above.

The countries covered in the poly (ADP-Ribose) polymerase (PARP) inhibitors market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the poly (ADP-Ribose) polymerase (PARP) inhibitors market due to the presence of major key players, high healthcare expenditure and well-developed healthcare sector in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing research and development activities, and because of the increasing population

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Poly (ADP-Ribose) polymerase (PARP) inhibitors market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Poly (ADP-Ribose) polymerase (PARP) inhibitors market Share Analysis

Poly (ADP-Ribose) polymerase (PARP) inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global poly (ADP-Ribose) polymerase (PARP) inhibitors market research.

The major players covered in the poly (ADP-Ribose) polymerase (PARP) inhibitors market report are Pfizer Inc., CLOVIS ONCOLOGY, AstraZeneca, Merck & Co., Inc., Myriad Genetics, Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Inc., AbbVie Inc., Myriad Genetics, Inc., Teva Pharmaceutical Industries Ltd., Checkpoint Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Artios Pharma, Genentech, Inc., www.inotekcorp.com, onxeo, Bristol-Myers Squibb Company, Sierra Oncology, Inc., Karyopharm Therapeutics, ONO PHARMACEUTICAL CO., LTD., Repare Therapeutics among other domestic and global players.  Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.


SKU-

Why Choose Us


Frequently Asked Questions